

Utilization of Hydrotropes on Solubilization of Tenoxicam in Aqueous Solution

Abstract

Hydrotropy is a unique solubilization technique utilized to depict the increase in the solubility of a solute by the addition of a second solute (in large amount) resulting in an increase in the aqueous solubility of a solute of interest. Therapeutic effectiveness of a drug depends on its aqueous solubility and bioavailability. The purpose of the study was to establish tenoxicam solubility in hydrotropes at very low concentrations as well as explore solubilization behavior of the drug in mixed hydrotropic systems at very low concentrations.

The methodology involved the use of rotary flask shaker at room temperature to determine the solubility of tenoxicam in water, hydrotropes (sodium benzoate, sodium citrate, urea) and mixed hydrotropes.

The results showed that sodium benzoate gave the most increase in the aqueous solubility of tenoxicam when compared to other hydrotropes. However, the highest aqueous solubility fold increase of tenoxicam (about 92 fold-increase) was produced by sodium benzoate and sodium citrate mix at 6:2 ratio. The decrease in standard free energy pointed out the spontaneity of the solubilization process.

In conclusion, the study showed that mixed hydrotropes are better to be utilized in the solubilizing of tenoxicam in aqueous solution.

Keywords: Tenoxicam, hydrotropy, mixed hydrotropy, solubilization

Introduction

Combinational chemistry, high throughput screening, as well as genomics have accelerated attrition of chemical compounds that lack high probability of successful development. A number of these new chemical compounds are highly hydrophobic and poorly water soluble. Aqueous solubility is a very vital physicochemical property for drug because low aqueous solubility can limit parenteral products development as well as the bioavailability of orally administered dosage forms [1]. Thus, it becomes imperative that finding effective solubilizing systems suitable for a wide range of poorly aqueous soluble drugs will immensely assist in pharmaceutical products development [2]. Several solubilizing systems have been utilized to enhance the aqueous solubility of poorly water soluble drugs and they include: (i) particle size reduction (micronization, nanosuspension) [3,4]; crystal habit modification (polymorphs, pseudopolymorphs) [5]; complexation (utilization of complexing agents) [6]; drug dispersion in carriers (eutectic mixtures, solid dispersions) [7]; micellization (utilization of surfactants) [8,9]; cosolvency (utilization of cosolvents) [10,11]; chemical modification (salts, prodrugs)

[12,13,14]; microemulsion [15]; nanoemulsion [16]; self-emulsifying systems [17], and hydrotropy [18].

Therefore, the present study was aimed at using hydrotropic systems to enhance the aqueous solubility of tenoxicam.

Hydrotropy is a phenomenon of solubilization entailing addition of large amount of second solute to produce in an increase in the aqueous solubility of another solute [19,20]. It designates increase in aqueous solubility due to the presence of large amount of additives. Additives or salts that increase the solubility of chemical compounds in a given solvent are said to “salt in” the solute whereas those salts that decrease the solubility are said to “salt out” the solute. A good hydrotrope has to have high water solubility while maintaining hydrophobicity. Invariably, an effective hydrotropic solubilization will depend on the balance between these two counteracting properties.


Hydrotropic agents are ionic organic salts [21]. Typical examples are sodium benzoate, sodium salicylate, urea, nicotinamide, sodium citrate, ibuprofen sodium, sodium acetate, sodium p-toluenesulfonate and N,N-dimethylbenzamide (a nonionic hydrotrope). Nicotinamide or its derivatives (for example N,N-diethylnicotinamide) are the most widely investigated hydrotropes by chemical or pharmaceutical analysts [22,23].

Hydrotropes have been classified into: (i) aromatic hydrotropes (nonionic) such as nicotinamide, sodium salicylate, sodium p-toluenesulfonate, N,N-dimethylbenzamide and N,N-diethylnicotinamide, (ii) urea and its derivatives (iii) aromatic alcohols, iv) organic metal salts and organic acids and (v) surfactants.

Hydrotropic solubilization mechanisms have been reported to include: (a) complexation [24], (b) molecular self-aggregation [25], (c) changes in the nature or structure of the solvent [26].

Mixed hydrotropic solubilization technique enhances the solubility of poorly soluble drugs using blends of hydrotropic agents. The technique provides synergistic enhancement effect on the solubility of poorly soluble drugs, as well as reducing the large total concentrations of hydrotropic agents necessary to produce desired increase in aqueous solubility [19].

Tenoxicam (Scheme 1), a non-steroidal antiinflammatory (NSAID) agent of the oxicam family, is chemically defined as 4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno (2, 3-e)-1, 2-thiazine-3-carboxamide-1, 1 dioxide) and having a molecular formula of $C_{13}H_{11}N_3O_4S_2$ and molar mass of $337.37 \text{ g}\cdot\text{mol}^{-1}$.



Scheme 1: Chemical structure of tenoxicam

It has anti-inflammatory, analgesic, and antipyretic properties, and clinically used in the treatment of rheumatic and arthritic diseases [27]. Tenoxicam solubility in water is very low (14 µg/ml) thus considered as practically insoluble drug.

To enhance aqueous solubilization of tenoxicam, some approaches such as phenolic cocrystals and salts [28], cosolvency [29,30], micellar solubilization [31], solid dispersion [31], and complexation [32] have been reported in literature.

Literature review has revealed that tenoxicam is practically insoluble in water and that no study on its aqueous solubility enhancement by hydrotropic technique has been reported.

Therefore, it was considered of interest to investigate the aqueous solubility enhancement of tenoxicam by hydrotropic technique. We envisage that the enhancement of its aqueous solubility could potentially alleviate the drug problems that limit its clinical utilization.

Experimental

Materials and Methods:

Tenoxicam was purchased from Sigma Chemical Company (St. Louis, MO, USA). The water used in this study was highly pure deionized water and obtained from Milli-Q water purification unit (Berlin, Germany). Sodium benzoate, sodium citrate and urea were purchased from Fischer Scientific, USA.

Drug solubility determination: Tenoxicam solubility was determined using saturating shake-flask method. Briefly, an excess amount of drug was added to screw capped 10 ml vials containing 5 ml of purified water, different concentrations of hydrotropes respectively. The vials and the mixtures were shaken for 48 h at room temperature ($25 \pm 1^\circ\text{C}$) on Rotary Flask Shaker at a speed of 125 rpm to achieve equilibration. Following equilibration, the samples were filtered through 0.45 µm disk filter and the supernatants were suitably diluted. The amount of tenoxicam was determined by measuring absorbance at 281 nm. Triplicate determinations on solubility experiments were carried out.

Results:

Calibration of tenoxicam:

A plot (Figure 1) of the absorbance versus concentration of tenoxicam is linear curve within the concentration range of 4 – 24 $\mu\text{g/ml}$. The correlation coefficient of the curve was found to be 0.9942. The regression equation defining the linearity of the curve is $A = 0.009C + 0.015$.




Figure 1. Calibration curve of tenoxicam

Tenoxicam solubility in hydrotropes:

The experimental aqueous solubility data for tenoxicam as function of the hydrotropes concentrations are given in Tables 1, 2 respectively. Plot of data in Table 1 is presented in Figure 2. The data show that sodium benzoate gave the most increase in the aqueous solubility of tenoxicam when compared to other hydrotropes (sodium citrate and urea respectively) utilized in the present study. Sodium benzoate at the highest concentration (10% w/v), gave about 82-fold increase in the aqueous solubility of tenoxicam. At the same concentration level, sodium citrate provided about 67-fold increase while urea gave about 9-fold increase in the aqueous solubility of tenoxicam. The correlation coefficients obtained from the curves in Figure 2 are 0.9918, 0.9905 and 0.9895 for sodium benzoate, sodium citrate and urea respectively.

The data in Table 2 provide the aqueous solubility of tenoxicam in mixed hydrotropes. The results show that sodium benzoate and urea mix at a ratio of 6:1 produced 89-fold increase in the aqueous solubility of tenoxicam. At the same mix ratio (6:1), sodium citrate and urea as well as

sodium benzoate and sodium citrate gave about 74-fold and 79-fold increase respectively in the aqueous solubility of tenoxicam.

However, the highest aqueous solubility fold increase of tenoxicam (about 92 fold-increase) was produced by sodium benzoate and sodium citrate mix at mix ratio of 6:2. The standard free energy (ΔG°) involved in the solubilization of tenoxicam in hydrotropes were evaluated and the results presented in Table 3.

Table 1: Effect of urea, sodium benzoate, sodium citrate on the aqueous solubility of tenoxicam

Concentration of hydrotropes (% w/v)	Solubility ($\mu\text{g/ml}$)					
	Sodium benzoate	Enhancement ratio (ER)	Sodium citrate	ER	Urea	ER
0.0	94.06 \pm 0.29	1.0	94.06 \pm 0.29	1.0	94.06 \pm 0.29	1.0
1.0	4344.12 \pm 0.53	46.18	2455.67 \pm 1.49	26.11	553.09 \pm 0.53	5.88
2.0	4805.15 \pm 1.00	51.09	2954.63 \pm 0.49	31.41	631.03 \pm 0.26	6.71
4.0	5841.23 \pm 0.47	62.10	4300.00 \pm 3.45	43.72	660.93 \pm 0.54	7.03
6.0	6570.12 \pm 1.00	69.85	4787.89 \pm 0.68	50.90	730.02 \pm 1.06	7.76
8.0	7143.74 \pm 0.99	75.95	5717.22 \pm 0.59	60.78	785.59 \pm 0.56	8.30
10.0	7706.18 \pm 0.70	81.93	6341.23 \pm 0.84	67.42	844.43 \pm 1.04	8.98




Figure 2: Plot of total solubility of tenoxicam versus hydrotrope concentration

Table 2: Effect of mixed hydrotropes on the aqueous solubility of tenoxicam

Concentration of mixed hydrotropes (% w/v)		Solubility (µg/ml)	Enhancement ratio
Sodium benzoate	Urea		
6	1	8372.16±1.06	89.01
1	6	4702.06±1.99	49.99
2	6	4959.79±1.31	52.78
6	2	8846.39±1.12	94.05
Sodium citrate	Urea		
6	1	6959.79±0.73	73.99
1	6	3042.27±1.14	32.34
2	6	4124.74±0.56	43.85

6	2	5629.80±0.85	59.85
Sodium benzoate	Sodium citrate		
6	1	6341.24±1.01	78.60
1	6	7392.78±1.48	67.42
2	6	5980.00±1.00	63.58
6	2	8609.28±1.55	91.53

Table 3. Solubilization parameters (hydrotrope-water partition coefficient and standard free energy of hydrotropic solubilization).

Concentration of hydrotrope (%w/v)	Sodium benzoate		Sodium citrate		Urea	
	P	ΔG°	P	ΔG°	P	ΔG°
0.0						
1.0	45.18	-9441.16	25.10	-7984.88	4.88	-3927.30
2.0	49.80	-9682.38	30.41	-8460.34	5.71	-4316.47
4.0	61.10	-10189.03	44.72	-9415.81	6.03	-4451.57
6.0	68.85	-10484.90	49.90	-9687.35	6.76	-4734.69
8.0	74.95	-10695.23	59.78	-10134.92	7.35	-4942.01
10.0	80.93	-10885.41	66.42	-10395.88	7.98	-5145.76

Discussion:

The linearity of the calibration curve of tenoxicam indicates that Beer's law was obeyed in the concentration range of 4-24 $\mu\text{g/ml}$.

Difference in chemical structures of the hydrotropes, were considered to be responsible for the hydrotropic effects on tenoxicam aqueous solubility. Sodium benzoate which produced very strong effect on the solubility enhancement of tenoxicam is the only solute with aromatic moiety out of the three hydrotropes investigated. Previous study has noted that aromatic moieties in the solute significantly favor the hydrotropic effect on the solubility enhancement of poorly aqueous soluble drugs [33]. The report also pointed out that a good hydrotrope while maintaining hydrophobicity should also have high water solubility.

Mixed hydrotropes at very low concentrations gave much better aqueous solubility enhancement of tenoxicam when compared to single hydrotropes. Previous reports have observed that mixed hydrotropes in lower concentration reduce the use of large total concentration of hydrotropic agents necessary to produce desired increase in solubility [34]. Based on Figure 2, we assume that the relationship between total drug solubility in a hydrotrope solution and hydrotrope concentration could be explained by the following equation:

$$S_{\text{tot}} = S_w + kC_{\text{hydro}} \quad \text{----- 1}$$

where C_{hydro} is the concentration of hydrotrope and k is the solubilization capacity. The solubilization capacity k is determined from the slope of the plot of the total solubility of the drug versus hydrotrope concentration.

Considering the solubilization of tenoxicam in hydrotropes as a thermodynamic process and molecular self-association or formation of micelle-like structure to be the mechanism of solubilization, then the standard free energy (ΔG°) involved in the solubilization can be evaluated using the following equation [35]:

$$\Delta G^\circ = -RT \ln P \quad \text{----- 2}$$

where P is the ratio of the amount of drug in water to the amount of drug in self-associated molecules S_{tot} : is the total drug solubility in hydrotrope; S_w is the drug solubility in water; R is the gas constant; and T is the absolute temperature. The hydrotrope-water partition coefficient (P) can be calculated from the equation below:

$$P = S_{\text{tot}} - S_w / S_w \quad \text{----- 3}$$

The decrease in standard free energy (Table 3), indicate the spontaneity of the solubilization process.

Conclusion:

Solubility enhancement is one of the advantages of hydrotropes. Sodium benzoate out of the three hydrotropes investigated, showed the best solubility enhancement for tenoxicam. This is probably due to the aromatic moiety in its chemical structure thus explaining different hydrophobicity between sodium benzoate, sodium citrate and urea. Mixed hydrotropes at lower concentrations gave much higher enhancement ratio in comparison with single hydrotropes. Finally, we suggest the utilization of mixed hydrotropes in solubilizing tenoxicam in aqueous solution.

References

1. Kapetanovic I.M., (2008). Computer-aided drug discovery and development (CADD): In silico-chemico-biological approach, *Chemico-Biological Interactions*, 171, pp. 165- 176.
- 2.S.H. Yalkowsky, T.J. Roseman, Solubilization of drugs by cosolvents, *Techniques of Solubilization of Drugs*, Edited by Yalkowsky, S.H. Marcel Dekker, Inc., New York. 1981, pp. 91–134.
3. Prakash Khadka, Jieun RO. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability, *Asian Journal of Pharmaceutical Sciences*. 2014; 9:304-316.
4. Samar Afifi A, Maha Hassan A. Nanosuspension: An emerging trend for bioavailability enhancement of etodolac. *International Journal of Polymer Science*. 2015, 1-15.
5. Keshav Jindal. Review on Solubility: A Mandatory Tool for Pharmaceuticals. *International Research Journal of Pharmacy*. 2017; 8(11):11-15.
6. Li, P., Zhao, L.W. and Yalkowsky, S.H. (1999) Combined Effect of Cosolvent and Cyclodextrin on Solubilization of Non-Polar Drugs. *Journal of Pharmaceutical Sciences*, 88, 1107-1111.
7. Sandeep Kumar, Pritam Singh. Various techniques for solubility enhancement: An overview. *The Pharma Innovation Journal*. 2016; 5(1):23-28.
8. Mbah, C.J. (2006) Solubilization of valsartan by aqueous glycerol, polyethylene glycol and micellar solutions. *Die Pharmazie*, 61, 322-324.
9. Avinash Dhobale V, Gunesh Dhembre N. Solubility enhancement techniques A review, *IAJPS*. 2018; 05(04):2798-2810.
10. C. J. Mbah, C. M. Onah. Studies on the potential vehicles (co-vehicles) for formulating intranasal solution of lamotrigine. *Pharmaceutical Chemistry Journal*, 2023; 57(4): 501-506.
11. Sneha Jagtap, Chandrakant Magdum. Solubility enhancement technique: A review. *Journal of Pharmaceutical Science and Research*. 2018; 10(9):2205- 2211.
12. Zhao, L., Li, P. and Yalkowsky, S.H. (1999) Solubilization of fluasterone. *Journal of Pharmaceutical Sciences*, 88, 967-969
13. Tegeli VS., Thorat YS., Review on concepts and advances in prodrug technology, *International Journal of Drug Formulation & Research* 1(3), 2010: 32-57.
14. Bhosle D, Bharambe S, Gairola N, and Dhaneshwar SS, Mutual prodrug concept: Fundamentals and applications. *Indian Journal of Pharmaceutical Sciences* 68, 2006: 286-294.
15. Cho, H.-J., Ku, W.-S., Termsarasab, U., Yoon, I., Chung, Ch.-W., Moon, H. T., and Kim, D.-D., (2012). Development of udenafil-loaded microemulsions for intranasal delivery: In vitro and in vivo evaluations. *Inter. J. Pharm.*, Vol. 423, No. 2,. Pp. 153-160.

16. Shafiq, S., Shakeel, F., Talegaonkar, S., Ahmed, F.J., Khar, R.K. and Ali, M. (2007) Development and bioavailability assessment of ramipril nanoemulsion formulation. *European Journal of Pharmaceutics and Biopharmaceutics*, 66, 227-243.
17. Salawi Ahmad. Self-emulifying drug delivery systems: A novel approach to deliver drugs. *Drug Deliv* 2022;29(1):1811-1823.
18. Akhilesh Kumar Jain. Solubilization of indomethacin using hydrotropes for aqueous injection. *European Journal of Pharmaceutics and Biopharmaceutics*. 2008; 68:701-714.
19. Rajawardhan Reddy M, Prasanna Kumar D. A Review on hydrotrophy. *Journal of Pharma Research*. 2013; 2(4):5-6.
20. A.T. Praveena, and J.L. Arun. (2020). A Review on hydrotropic solubilization: A novel approach for solubility enhancement of poorly water soluble drugs. *International Journal of Research and Review*, 7(10), 472-483.
21. Saleh AM, El-Khordagui LK. 1985. Hydrotropic agents: A new definition. *Int J Pharm* 24:231–238.
22. Lee SC, Acharya G, Chang CJ, Park K. 2003. Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. *Pharm Res* 20:1022–1030.
- 23 [JI Young Kim, Sungwon Kim, Michelle Papp, Kinam Park, Rodolfo Pinal .Hydrotropic solubilization of poorly water-soluble drugs. *Journal of Pharmaceutical Sciences*, Vol. 99, 3953–3965 (2010).
24. Sanghvi R, Evans D, Yalkowsky SH. 2007. Stacking complexation by nicotinamide: A useful way of enhancing drug solubility. *Int J Pharm* 336:35–41.
25. Charman WN, Lai CSC, Craik DJ, Finnin BC, Reed BL. 1993. Self-association of nicotinamide in aqueous solution: N.M.R. studies of nicotinamide and the mono and di-methyl substituted amide analogues. *Aust J Chem* 46:377–385.
26. Bauduin P, Renoncourt A, Kopf A, Touraud D, Kunz W. 2005. Unified concept of solubilization in water by hydrotropes and cosolvents. *Langmuir* 21:6769–6775.
27. Todd PA, Clissold SP. Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatid diseases. *Drugs* 1991; 41(4): 625-646.
28. Geetha Bolla, Palash Sanphui, Ashwini Nangia. Solubility advantage of tenoxicam phenolic cocrystals compared to salts. *Cryst. Growth Des*. 2013, 13, 5, 1988–2003.
29. Ming-Kung Yeh, Li-Chien Chang, and Andy Hong-Jey Chiou. Improving tenoxicam solubility and bioavailability by cosolvent system. *AAPS PharmSciTech*, Vol. 10, No. 1, March 2009.
30. Faiyaz Shakeel, Nazrul Haq , Fars K. Alanazi, Ibrahim A. Alsarra. Solubility and thermodynamics of tenoxicam in (PEG-400 + water) binary solvent systems at different temperatures . *Journal of Molecular Liquids* 213 (2016) 221–227.
31. Fetuoh MI, Ismail S, El-Harras SA, Abbas M. Solubilization of tenoxicam via different techniques. *Bull Pharm Sci Assiut University*, 2002; 26(1): 53-68.

32. Edurne Larrucea, Adriana Arellano, Susana Santoyo, and Pilar Ygartua. Study of the complexation behavior of tenoxicam with cyclodextrins in solution: Improved solubility and percutaneous permeability. *Drug Development and Industrial Pharmacy*, 28(3), 245–252 (2002).
33. Lee J, Lee SC, Acharya G, Chang CJ, Park K. 2003. Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. *Pharm Res* 20:1022–1030.
34. Kadam SV, Shinkar DM, Saudagar RB. Review on solubility techniques. *International Journal of Pharmacy and Biological Sciences*. 2013; 1:462-475.
35. A.P. and Tavares, L.C. (2005) Micellar solubilization of drugs. *Journal of Pharmaceutical Sciences*, 8, 147-16.

UNDER PEER REVIEW